- Acharya Manish Grover, Founder and Managing Director of Jeena Sikho Lifecare Limited (market capitalisation: ₹8,775.63 crore), has invested 1.37% in Invicta Diagnostic Limited through a secondary transaction. The transaction includes a partial stake sale by the promoter group members and comes ahead of Invicta Diagnostic’s proposed public offering of ₹28.12 crore. This investment follows Invicta Diagnostic’s fundraising round in June 2025, where the company received backing from well-known investors including Sandeep Singh, Siddharth Nahar (Sapphire Capital), and Grobiz SME Opportunity Fund ahead of filing its DRHP.
- Invicta Diagnostic Limited filed its DRHP in July this year and the IPO comprises a fresh issue of up to 33,08,800 Equity Shares with a face value of ₹10 each and has received approval from the Stock Exchange in August 2025 earlier this year.
- The company intends to utilise up to ₹21.11 crore of the total IPO proceeds to fund its capital expenditure for purchasing medical equipment towards the establishment of five new diagnostic centres in Maharashtra and plans to use remaining capital for general corporate purposesand issue expenses.
- Socradamus Capital Private Limited is the sole Book Running Lead Manager to the issue, and Bigshare Services Private Limited is the Registrar to the issue.
November 22, 2025: IPO-bound Invicta Diagnostic Limited, announced a strategic investment of 1.37%in a secondary transaction from Acharya Manish Grover, Founder and Managing Director of Jeena Sikho Lifecare Limited.The investment was made in exchange for 1.27 Lakh equity shares, underscores investor confidence in the company’s growth outlook and upcoming public offering. This investment follows Invicta Diagnostic’s fundraising round in June 2025, where the company received backing from well-known investors including Sandeep Singh, Siddharth Nahar (Sapphire Capital), and Grobiz SME Opportunity Fund ahead of filing its DRHP.
Speaking about the investment,Mr. Rohit Prakash Srivastava,the Promoter of Invicta Diagnostic Limited, said, “We are honoured to have the trust and backing of such leadersof the industry. Our investorsnot only validates our business model, but also strengthens our vision of building a future-ready and scalablediagnostics chain as we move towards our IPO.”
Invicta Diagnostic Limited, which offers comprehensive radiology and pathology solutions in the Mumbai Metropolitan Region (MMR), under the brand name ‘PC Diagnostics’,is looking to raise ₹28.12 Crore through its initial public offering comprising of a fresh issuance of up to 33,08,800 Equity Shareswith a face value of ₹10, through the book-built route.
Socradamus Capital Private Limited is the sole Book Running Lead Manager to the issue, and Bigshare Services Private Limited is the Registrarto the Issue.
Invicta Diagnostic Limited intends to utilise up to ₹21.11 crore of the total IPO proceeds to fund its capital expenditure for purchasing medical equipment towards the establishment of five new diagnostic centres in Maharashtra and plans to use remaining capital for general corporate purposes and issue expenses.
InvictaDiagnostic Limited’s operational network consists of a flagship centre located in Thane, which is the main hub; 3 other hub centres through the company’s subsidiaries; 3 spoke centres, including 1 spoke centre through its subsidiary; and 1 centralised laboratory co-located with one of the spoke centre.The company offers a range of approximately 60 routine and 487 specialized pathology tests and approximately 96 basic and 130 advanced radiology tests that cover a range of specialties and disciplines.
The businessand brand “PC Diagnostics” were conceptualised and founded by Dr. Ketan Jayantilal Jain and Dr. Sanket Vinod Jain, its Promoters and Non-Executive directors, who are first-generation entrepreneurs in healthcare with more than 15 years and 7 years of experience, respectively, in diagnostics business and both are radiologists.
The promoters of the company include Dr. Ketan Jayantilal Jain, Dr. Sanket Vinod Jain, Rohit Prakash Srivastava, Badal Kailash Naredi and Jayesh Prakash Jain. InvictaDiagnostic Limited has immensely benefitted from their vision and leadership, and they along with the senior management, have been instrumental in formulating and executing the strategy of the company.
For more information, please visit: https://www.pcdiagnostics.in/
Disclaimer: INVICTA DIAGNOSTIC LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the DRHP with the NSE Emerge. The DRHP is available on the website of BRLM and the website of NSE. Any potential investors should note that investment in equity shares involves a high degree of risk, and for details relating to the same, please refer to the DRHP, including the section titled “Risk Factors”, beginning on page 41.
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in ‘offshore transactions in reliance on Regulation S under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.
